Genmab (GMAB) has released an update.
Genmab’s revenue surged by 29% in the first nine months of 2024, reaching DKK 15,085 million, primarily driven by increased royalties from its collaborations and strong sales of its cancer treatments. The company received conditional marketing authorization in Europe for TEPKINLY®, expanding its portfolio and signaling growth potential. Genmab’s updated financial guidance reflects a robust performance, though it remains focused on disciplined investment strategies.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Phillip Securities Analyst Lifts Meta Price Target on Solid AI Potential
- Insider Trade: Carvana CFO Accumulates Shares Worth $37.7M
- 3 Penny Stocks to Watch Now, 11/7/24
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
